Cann Group (ASX:CAN) - CEO, Peter Crock
CEO, Peter Crock
Source: Cannabis Club Australia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical cannabis company Cann Group (CAN) has announced that investor Aurora Cannabis has dropped its stake in the company
  • Aurora sold its 11.84 per cent shareholding in Cann via off-market trades to a small number of buyers
  • Aurora said its plan to sell is consistent with its current strategic priorities
  • Nevertheless, Cann has reassured shareholders that Aurora’s decision will not impact its business plans
  • On the market today, Cann is down 7.14 per cent, trading for 39 cents per share

Medical cannabis company Cann Group (CAN) has announced that investor Aurora Cannabis has dropped its stake in the company.

On Friday, Aurora sold its 11.84 per cent shareholding in Cann via off-market trades to a small number of buyers.

Aurora said its plan to sell is consistent with its current strategic priorities.

Nevertheless, Cann has reassured shareholders that Aurora’s decision will not impact its business plans.

Currently, the company is “developing a growing and diversified supply base with business to business (B2B) customers in Australia and overseas and proceeding with plans to expand its manufacturing capacity.”

In August, the company’s 2020 financial year results came out. Cann’s full-year revenue slipped 56 per cent to $1.86 million compared to the previous financial year.

With the Mildura facility expansion, Cann is expecting around $15 million in revenue for the 2021 financial year.

On the market today, Cann is down 7.14 per cent, trading for 39 cents per share at 12:31pm AEDT.

CAN by the numbers
More From The Market Online

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported…

PYC Therapeutics takes Polycystic Kidney Disease drug to human trials

PYC Therapeutics takes its latest drug for Polycystic Kidney Disease, characterized by the formation of cysts…